Acquisition Opportunity Coriell Life Sciences was acquired by InformedDNA on March 19, 2025, indicating potential integration of pharmacogenomics and clinical decision support capabilities with InformedDNA’s network. This presents a chance to align product offerings, co-sell pharmacogenomics services, and expand reach through InformedDNA's existing customer base.

Pharmacogenomics Partnerships Past partnerships with Quest Diagnostics and involvement in pharmacy benefit management programs signal strong market receptivity for PGx testing and decision-support solutions. Leverage these signals to position CLS as a preferred pharmacogenomics provider for employer health plans, PBMs, and healthcare networks seeking cost containment and improved outcomes.

Cost Containment Credibility Award recognition for cost containment and the Corigen Medication Safety Program demonstrates CLS’s value proposition around reducing waste and costs. This can be highlighted to prospective buyers seeking ROI through precision medicine to lower adverse drug events and optimize therapy.

Market Positioning CLS operates in precision medicine with a global footprint and a focused client base including retirement systems, health plans, and employers. Target opportunities include large-scale plans and benefit managers looking to integrate pharmacogenomics into coverage policies and tiered benefit designs.

Growth Signals Recognition in industry awards and ongoing collaborations indicate momentum in the market. Engage with health plans and provider networks seeking innovative cost-saving safety programs and expanded pharmacogenomics capabilities to differentiate their offerings.